Cargando…

S100: FIRST PHASE 3 RESULTS FROM CARTITUDE-4: CILTA-CEL VERSUS STANDARD OF CARE (PVD OR DPD) IN LENALIDOMIDE-REFRACTORY MULTIPLE MYELOMA

Detalles Bibliográficos
Autores principales:	Einsele, Hermann, Yong, Kwee, Harrison, Simon, Mateos, Maria-Victoria, Moreau, Philippe, van de Donk, Niels W.C.J., Sidana, Surbhi, Popat, Rakesh, Lendvai, Nikoletta, Lonardi, Carolina, Slaughter, Ana, Schecter, Jordan, LI, Katherine, Zudaire, Enrique, Chen, Diana, Gilbert, Jane, Yeh, Tzu-Min, Pacaud, Lida, Patel, Nitin, Dhakal, Binod, San Miguel, Jesús
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Plenary Abstracts Session
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10428371/ http://dx.doi.org/10.1097/01.HS9.0000967308.47141.6f

Ejemplares similares

B09 CARTITUDE-2 COHORT B 18-MONTH FOLLOW-UP: CILTACABTAGENE AUTOLEUCEL (CILTA-CEL), A BCMA-DIRECTED CAR-T CELL THERAPY, IN PATIENTS WITH MULTIPLE MYELOMA (MM) AND EARLY RELAPSE AFTER INITIAL THERAPY
por: Zweegman, S., et al.
Publicado: (2023)

Efficacy and safety of cilta-cel in patients with progressive multiple myeloma after exposure to other BCMA-targeting agents
por: Cohen, Adam D., et al.
Publicado: (2023)

Incidence and management of CAR-T neurotoxicity in patients with multiple myeloma treated with ciltacabtagene autoleucel in CARTITUDE studies
por: Cohen, Adam D., et al.
Publicado: (2022)

P28 EFFICACY AND SAFETY OF CILTACABTAGENE AUTOLEUCEL (CILTA-CEL) IN PATIENTS WITH PROGRESSIVE MULTIPLE MYELOMA (MM) AFTER EXPOSURE TO NON-CELLULAR ANTI-B-CELL MATURATION ANTIGEN (BCMA) IMMUNOTHERAPY
por: van de Donk, N., et al.
Publicado: (2023)

Extrapolation of Survival Data Using a Bayesian Approach: A Case Study Leveraging External Data from Cilta-Cel Therapy in Multiple Myeloma
por: Palmer, Stephen, et al.
Publicado: (2023)

P899: REAL-WORLD ASSESSMENT OF TREATMENT PATTERNS AND OUTCOMES IN PATIENTS WITH LENALIDOMIDE-REFRACTORY RELAPSED/REFRACTORY MULTIPLE MYELOMA FROM THE OPTUM DATABASE
por: Dhakal, B., et al.
Publicado: (2022)

P46 SEER-MEDICARE DATABASE: REAL-WORLD TREATMENTS AND OUTCOMES IN PATIENTS WITH LENALIDOMIDE-REFRACTORY RELAPSED MULTIPLE MYELOMA TREATED WITH 1–3 PRIOR LINES OF THERAPY, INCLUDING A PI AND IMID
por: Einsele, H., et al.
Publicado: (2023)

P35 ANALYSIS OF DARATUMUMAB CLINICAL TRIALS: CHARACTERISTICS AND OUTCOMES IN PATIENTS WITH LENALIDOMIDE-REFRACTORY RELAPSED/REFRACTORY MULTIPLE MYELOMA TREATED WITH 1-3 PRIOR LINES OF THERAPY
por: Einsele, H., et al.
Publicado: (2023)

P959: CILTACABTAGENE AUTOLEUCEL IN LENALIDOMIDE-REFRACTORY PATIENTS WITH PROGRESSIVE MULTIPLE MYELOMA AFTER 1-3 PRIOR LINES OF THERAPY: CARTITUDE-2 BIOLOGICAL CORRELATIVE ANALYSES AND UPDATED CLINICAL DATA
por: Hillengass, J., et al.
Publicado: (2022)

B07: SAFETY AND EFFICACY OF CILTACABTAGENE AUTOLEUCEL, A CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY DIRECTED AGAINST B-CELL MATURATION ANTIGEN IN PATIENTS WITH MULTIPLE MYELOMA AND EARLY RELAPSE AFTER INITIAL THERAPY: CARTITUDE-2 RESULTS
por: van de Donk, NWCJ, et al.
Publicado: (2022)

P08: CARTITUDE-2 UPDATE: CILTACABTAGENE AUTOLEUCEL, A B-CELL MATURATION ANTIGEN–DIRECTED CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY, IN LENALIDOMIDE-REFRACTORY PATIENTS WITH PROGRESSIVE MULTIPLE MYELOMA AFTER 1-3 PRIOR LINES OF THERAPY
por: Einsele, H, et al.
Publicado: (2022)

Lenalidomide promotes the development of TP53-mutated therapy-related myeloid neoplasms
por: Sperling, Adam S., et al.
Publicado: (2022)

P23 EMAGINE/CARTITUDE-6: A RANDOMIZED PHASE 3 STUDY OF DVRD FOLLOWED BY CILTACABTAGENE AUTOLEUCEL VERSUS DVRD FOLLOWED BY AUTOLOGOUS STEM CELL TRANSPLANT IN TRANSPLANT-ELIGIBLE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA
por: Broijl, A., et al.
Publicado: (2023)

P971: ADJUSTED COMPARISON OF PATIENT REPORTED OUTCOMES FROM CARTITUDE-1 AND LOCOMMOTION COMPARING CILTACABTAGENE AUTOLEUCEL VERSUS REAL WORLD CLINICAL PRACTICE IN TRIPLE-CLASS EXPOSED MULTIPLE MYELOMA
por: Weisel, K., et al.
Publicado: (2022)

P922: ADJUSTED COMPARISONS OF CILTACABTAGENE AUTOLEUCEL WITH THERAPIES FROM REAL-WORLD CLINICAL PRACTICE: TWO-YEAR FOLLOW-UP ANALYSES FROM CARTITUDE-1 AND THE PROSPECTIVE LOCOMMOTION STUDY
por: Mateos, Maria-Victoria, et al.
Publicado: (2023)

S202: CARTITUDE-1 FINAL RESULTS: PHASE 1B/2 STUDY OF CILTACABTAGENE AUTOLEUCEL IN HEAVILY PRETREATED PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA
por: Munshi, Nikhil, et al.
Publicado: (2023)

Ciltacabtagene Autoleucel, an Anti–B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-Up
por: Martin, Thomas, et al.
Publicado: (2023)

Ciltacabtagene autoleucel in patients with relapsed/refractory multiple myeloma: CARTITUDE‐1 (phase 2) Japanese cohort
por: Ri, Masaki, et al.
Publicado: (2022)

Adjusted comparison of outcomes between patients from CARTITUDE-1 versus multiple myeloma patients with prior exposure to proteasome inhibitors, immunomodulatory drugs and anti-CD38 antibody from the prospective, multinational LocoMMotion study of real-world clinical practice
por: Mateos, Maria-Victoria, et al.
Publicado: (2022)

P961: CILTACABTAGENE AUTOLEUCEL, A BCMA-DIRECTED CAR-T CELL THERAPY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: 2-YEAR POST LPI RESULTS FROM THE PHASE 1B/2 CARTITUDE-1 STUDY
por: Lin, Y., et al.
Publicado: (2022)

The Efficacy and Safety of YAG Laser Vitreolysis for Symptomatic Vitreous Floaters of Complete PVD or Non-PVD
por: Lin, Tiezhu, et al.
Publicado: (2021)

PvdM of fluorescent pseudomonads is required for the oxidation of ferribactin by PvdP in periplasmic pyoverdine maturation
por: Sugue, Michael-Frederick, et al.
Publicado: (2022)

QCD and forward physics
por: Harland-Lang, Lucian
Publicado: (2019)

Long-lived particles
por: Cid Vidal, Xabier
Publicado: (2019)

SUSY and Dark Matter
por: Vranjes Milosavljevic, Marija
Publicado: (2019)

EWK Physics
por: Lee, Claire
Publicado: (2019)

Higgs Flavor and rare decays
por: Ilten, Philip
Publicado: (2019)

Introduction
por: Cid Vidal, Xabier
Publicado: (2019)

Top physics
por: Schoefbeck, Robert
Publicado: (2019)

Experimental Prospects in Flavour
por: Owen, Patrick Haworth
Publicado: (2019)

Panel debate
por: CERN. Geneva
Publicado: (2018)

EFT interpretations and BSM Higgs searches
por: Riva, Francesco
Publicado: (2019)

HH Production
por: Petit, Elisabeth
Publicado: (2019)

High pT and resonances
por: Hoepfner, Kerstin
Publicado: (2019)

Theoretical Prospects in Flavour
por: Isidori, Gino
Publicado: (2019)

Precision Higgs Physics: Higgs couplings
por: De Wit, Adinda
Publicado: (2019)

Quark-Gluon Plasma studies in Run 3 and 4
por: Lee, Yen-Jie
Publicado: (2019)

Particle production and collectivity across system size
por: Grosse-Oetringhaus, Jan Fiete
Publicado: (2019)

Prospects with light ions in Run 5 and heavy ions at HE-LHC
por: Milhano, Guilherme
Publicado: (2019)

RF acceleration
por: Napoly, Olivier
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_14hk01ihbie2t6tvii4ts3ob6t